Caroline Robert

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi Tyrosine kinase inhibition and grey hair
    Caroline Robert
    Lancet 361:1056. 2003
  2. ncbi Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
  3. ncbi [Cutaneous side effects of antiangiogenic agents]
    Caroline Robert
    Service de Dermatologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif
    Bull Cancer 94:S260-4. 2007
  4. ncbi Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Julien Autier
    Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Dermatol 144:886-92. 2008
  5. ncbi Advances in the management of cutaneous toxicities of targeted therapies
    Caroline Robert
    Institute Gustave Roussy, Villejuif, France
    Semin Oncol 39:227-40. 2012
  6. ncbi What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
    Caroline Robert
    Institute Gustave Roussy, 94805 Villejuif Cedex, France
    Oncologist 14:848-61. 2009
  7. ncbi [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]
    Caroline Robert
    Institut Gustave Roussy, Villejuif, France
    Med Sci (Paris) 27:850-8. 2011
  8. ncbi [What is new in oncodermatology?]
    C Robert
    Service de Dermatologie, Institut Gustave Roussy, Villejuif, France
    Ann Dermatol Venereol 135:S354-9. 2008
  9. ncbi Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
    Jean Philippe Arnault
    Department of Medical Oncology and Pathology, Institute Gustave Roussy, Villejuif, France
    Clin Cancer Res 18:263-72. 2012
  10. ncbi Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha
    Sophie Viaud
    Institut National de la Sante et de la Recherche Medicale, Unité 805, Villejuif, France
    PLoS ONE 4:e4942. 2009

Detail Information

Publications38

  1. ncbi Tyrosine kinase inhibition and grey hair
    Caroline Robert
    Lancet 361:1056. 2003
  2. ncbi Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
    ..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
  3. ncbi [Cutaneous side effects of antiangiogenic agents]
    Caroline Robert
    Service de Dermatologie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif
    Bull Cancer 94:S260-4. 2007
    ..It will help us understanding better skin pathophysiology, but, most of all, it will lead to more efficient symptomatic treatment for our patients...
  4. ncbi Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Julien Autier
    Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Dermatol 144:886-92. 2008
    ..To provide an accurate description and to evaluate the incidence and severity of cutaneous reactions induced by sorafenib tosylate, a new oral multikinase inhibitor...
  5. ncbi Advances in the management of cutaneous toxicities of targeted therapies
    Caroline Robert
    Institute Gustave Roussy, Villejuif, France
    Semin Oncol 39:227-40. 2012
    ..We will review the skin side effects of EGFR, VEGFR, KIT, platelet-derived growth factor receptor (PDGFR), and BCR-ABL inhibitors, as well as mTOR inhibitors...
  6. ncbi What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
    Caroline Robert
    Institute Gustave Roussy, 94805 Villejuif Cedex, France
    Oncologist 14:848-61. 2009
    ..However, the true advantage of these new drugs may depend largely on the characterization of predictive biomarkers of activity and subsequent targeting of responsive patients...
  7. ncbi [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]
    Caroline Robert
    Institut Gustave Roussy, Villejuif, France
    Med Sci (Paris) 27:850-8. 2011
    ..The challenges are now to identify biomarkers able to predict ipilimumab benefit and to know how to use ipilimumab in combination with new targeted therapies of melanoma in order to optimize the treatment efficacy...
  8. ncbi [What is new in oncodermatology?]
    C Robert
    Service de Dermatologie, Institut Gustave Roussy, Villejuif, France
    Ann Dermatol Venereol 135:S354-9. 2008
    ..Besides melanoma, the scoop of the year was the discovery of a defective oncogenic polyomavirus which is very likely to be responsible for Merkel cell carcinoma...
  9. ncbi Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
    Jean Philippe Arnault
    Department of Medical Oncology and Pathology, Institute Gustave Roussy, Villejuif, France
    Clin Cancer Res 18:263-72. 2012
    ..We carried out a clinical, pathologic, and molecular study of skin lesions occurring in patients receiving sorafenib...
  10. ncbi Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha
    Sophie Viaud
    Institut National de la Sante et de la Recherche Medicale, Unité 805, Villejuif, France
    PLoS ONE 4:e4942. 2009
    ..Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors and induce tumor regression in vivo...
  11. ncbi Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients
    Cedric Menard
    Institut National de la Sante et de la Recherche Medicale INSERM, Unit U805 Tumor immunology and immunotherapy, Villejuif, France
    Cancer Res 69:3563-9. 2009
    ..The NK cell IFN-gamma production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with IM...
  12. ncbi Dermatologic symptoms associated with the multikinase inhibitor sorafenib
    Caroline Robert
    Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France
    J Am Acad Dermatol 60:299-305. 2009
    ..The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms...
  13. ncbi Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Cedric Menard
    Center of Clinical Investigations, CBT507, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 14:5242-9. 2008
    ..However, mechanisms of action and surrogate immunologic markers of efficacy have not been reported thus far...
  14. ncbi ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway
    Ahmed Hamai
    Institut National de la Sante et de la Recherche Medicale, U753, Laboratoire d Immunologie des Tumeurs Humaines Interaction effecteurs cytotoxiques système tumoral, Institut Gustave Roussy PR1 and IFR 54, Villejuif, France
    Cancer Res 68:9854-64. 2008
    ..The present study shows that a shift in ICAM-1 expression, which was associated with an activation of the PI3K/AKT pathway, can be used by metastatic melanoma cells to escape CTL-mediated killing...
  15. ncbi Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Sandrine Faivre
    Department of Medicine, Gustave-Roussy Institute, Villejuif, France
    J Clin Oncol 24:25-35. 2006
    ..Future studies may consider including prospective imaging techniques such as high frequency ultrasound to monitor tumor density...
  16. ncbi Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL
    Houssem Benlalam
    Institut National de la Santé et de la Recherche Médicale Unite 753, Institut Fédératif de Recherche 54, Villejuif, France
    J Immunol 182:2654-64. 2009
    ..Our results indicate that gap junctions facilitate an effective CTL-mediated destruction of endothelial cells from the tumor microenvironment that may contribute to the control of tumor progression...
  17. ncbi Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:1801-9. 2007
    ..To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN alpha-2a in advanced renal cell carcinoma (RCC) or melanoma...
  18. ncbi Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
    Alexander M M Eggermont
    Institut de Cancerologie Gustave Roussy, Villejuif, Paris, France
    Curr Opin Oncol 24:137-40. 2012
    ..Patients with an ulcerated melanoma do much worse than patients with a nonulcerated melanoma with the same breslow thickness. Ulceration may indicate a separate biologic entity...
  19. ncbi Anti-CTLA-4 antibody adjuvant therapy in melanoma
    Alexander M M Eggermont
    Institut d Oncologie Gustave Roussy, Villejuif, France
    Semin Oncol 37:455-9. 2010
    ..The EORTC 18071 trial will reach full accrual in 2011 and thus results are expected in 2013 or 2014...
  20. ncbi Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas
    Caroline Kannengiesser
    Service de Génétique and CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    Mol Oncol 1:425-30. 2008
    ....
  21. ncbi Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses
    Stephan Roux
    INSERM U805, Villejuif, France
    Cancer Immunol Immunother 57:1291-300. 2008
    ..We addressed whether tumor-associated antigens released after ECT could induce an efficient systemic immunity when associated with an appropriate immunoadjuvant...
  22. ncbi Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
    Alexander M M Eggermont
    Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 48:218-25. 2012
    ..Adjuvant interferon has modest activity in melanoma patients at high risk for relapse. Patient selection is important; stage and ulceration of the primary tumour are key prognostic factors...
  23. ncbi New drugs in melanoma: it's a whole new world
    Alexander M M Eggermont
    Institut de Cancerologie Gustave Roussy, Villejuif, Paris Sud, France
    Eur J Cancer 47:2150-7. 2011
    ..Adjuvant trials with BRAF and MEK inhibitors are in the planning phase. Never was there a more exciting period in the world of melanoma treatment...
  24. ncbi [Major therapeutic advances in the treatment of metastatic melanoma]
    Christine Mateus
    Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 99:619-25. 2012
    ..New combination therapies and additional targeted and immunotherapy agents are exciting perspectives that make us more optimistic for the future of metastatic melanoma treatment...
  25. ncbi Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    Caroline Robert
    Institute Gustave, Roussy, Villejuif, France
    N Engl J Med 364:2517-26. 2011
    ..We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma...
  26. ncbi Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Christophe Borg
    Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 114:379-88. 2004
    ..These data point to a novel mode of antitumor action for Gleevec...
  27. ncbi [Epithelial and melanic skin tumours]
    Christine Mateus
    Service de Dermatologie, Institut Gustave-Roussy, Villejuif Cedex
    Rev Prat 57:2067-79. 2007
  28. ncbi Update on the role of ipilimumab in melanoma and first data on new combination therapies
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Siena, Italy
    Curr Opin Oncol 25:166-72. 2013
    ..This article provides an update on the therapeutic role of the monoclonal antibody ipilimumab in melanoma. Recent therapeutic combinations, as well as directions for further investigations, will also be discussed...
  29. ncbi Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment
    Linda Chami
    Imaging Department Institut Gustave Roussy, Villejuif, France
    Clin Cosmet Investig Dermatol 4:1-6. 2011
    ....
  30. ncbi Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma
    Mojgan Movassagh
    , Department of Pathology, Dermatology Unit, Institut Gustave-Roussy, 94805 Villejuif Cedex, France
    Cancer Res 64:2192-8. 2004
    ....
  31. ncbi Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy
    Nadia Haddy
    INSERM, U605, Villejuif, France
    Radiother Oncol 93:377-82. 2009
    ..This paper presents the incidence of differentiated thyroid adenomas and carcinomas after radiotherapy in this cohort...
  32. ncbi RAF inhibition and induction of cutaneous squamous cell carcinoma
    Caroline Robert
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    Curr Opin Oncol 23:177-82. 2011
    ..The purpose of this review is to discuss the mechanisms as well as the management and implications of this unexpected side-effect...
  33. ncbi [Management of recurrent soft tissue sarcoma of the retroperitoneum]
    Sylvie Bonvalot
    Departement de Chirurgie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 91:845-52. 2004
    ..Adequate management at the time of primary presentation is likely to afford the best chance for long-term survival...
  34. ncbi Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Caroline Robert
    Ann Intern Med 143:313-4. 2005
  35. ncbi CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner
    Francois Ghiringhelli
    ERM 0208, Institut National de la Sante et de la Recherche Medicale INSERM, University of Paris XI, France
    J Exp Med 202:1075-85. 2005
    ..Human NK cell-mediated tumor recognition could also be restored by depletion of T reg cells from tumor-infiltrating lymphocytes. These findings support a role for T reg cells in blunting the NK cell arm of the innate immune system...
  36. ncbi Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases
    Florent Grange
    Department of Dermatology, Hopital Robert Debre, avenue du Général Koenig, Reims 51100, France
    Arch Dermatol 143:1144-50. 2007
    ....
  37. ncbi Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients
    Nadege Bercovici
    IDM, Hopital Europeen Georges Pompidou, Unité d Immunologie Biologique, EA 4054 Université Paris, France
    J Immunother 31:101-12. 2008
    ..The differential expression of perforin and IFN-gamma by antitumor and antiviral CD8+ T cells supports that the sole use of IFN-gamma production to monitor T cells overlooks functional T-cell subpopulations triggered by vaccines...
  38. ncbi Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
    Bruce Elliott
    Royal Surrey County Hospital Guildford, Guildford, United Kingdom
    Clin Cancer Res 13:3825-30. 2007
    ..The aim of this study was to investigate the prognostic importance of the maximal density of mature DCs in SLNs...